Cachexia in Cancer Patients: Systematic Literature Review

Timotius I. Hariyanto¹  Andree Kurniawan²

¹Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, Banten, Indonesia
²Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, Banten, Indonesia

Address for correspondence  Timotius I. Hariyanto, MD, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, Banten 15811, Indonesia (e-mail: timotius.hariyanto95@gmail.com).

Abstract

Introduction  Cachexia in cancer patients, especially in advanced stage, is recently known as an emerging problem. Cachexia occurs in about half of all patients with neoplastic disease. The diagnosis of cachexia needs comprehensive evaluation of body weight and body composition for several months. Cachexia will give negative impacts such as increased mortality, chemotoxicity, and decreased quality of life. Here, we review the current evidence describing the definition, stages, mechanisms, diagnosis and treatment of cachexia in cancer patients.

Methods  We identified 75 studies and/or review articles evaluating cachexia and weight loss in cancer patients by searching PubMed and EMBASE databases.

Results  Cachexia is reported across all stages and types of cancers. The most recent definition of cachexia is reported in a 2011 paper by International Consensus. The mechanism of cachexia in cancer is complex and involved many factors which elaborate together to produce cachexia. The diagnostic evaluation and cut-off measurement of cachexia, especially in cancer varied across studies. The loss of weight that happens during chemotherapy will make a poor prognosis. Cachexia can worsen chemotherapy toxicity. Combination of dietary modification and exercise with supplementation of medication that control appetite and inflammation are important in the management of cachexia in cancer patients.

Conclusion  Patients with cancer are the population at risk for developing cachexia before and after chemotherapy. Cachexia diagnosis needs evaluation of body weight and body composition. Nonpharmacological treatments, such as dietary modification and physical exercise, are the best strategy to reduce cachexia in cancer patients.

Keywords
► cachexia
► weight loss
► cancer

Introduction

Cachexia is a disorder characterized by the involuntary loss of body weight in addition to loss of homeostatic control of both energy and protein balance.¹ Cachexia is associated with several chronic diseases and in particular, it can be observed as a paraneoplastic syndrome in patients affected by cancer. Cachexia pathophysiology is associated with systemic inflammation that involved many cytokines and mediators, negative protein and energy balance, and an involuntary loss of lean body mass with lipolysis.² Cachexia can have a profound impact on quality of life (QOL), symptom burden, and a patient's sense of dignity. It is a very serious complication, as weight loss during cancer treatment is associated with more chemotherapy-related side effects, fewer completed cycles of chemotherapy, and decreased survival rates.¹ Cancer cachexia, at least in a mild form, occurs in approximately 50% of all patients with neoplastic disease and is a poor prognosticator.⁴ Importantly, more than 20% of patients with diagnosis of cancer will die due to cancer cachexia.⁵ ⁶

published online  June 13, 2020
DOI https://doi.org/10.1055/s-0040-1713701
ISSN 2454-6798.
©2020 Spring Hope Cancer Foundation & Young Oncologist Group of Asia

License terms
Current therapies focus on palliation of symptoms and the reduction of distress of patients and families rather than cure. By combining pharmacological and nonpharmacological interventions, the multifaceted mechanisms of this complex syndrome could be addressed simultaneously, resulting in improved protein and caloric intake, gains in muscle and fat, and better physical function.

Search Strategies
A comprehensive search of literature was conducted in the PubMed (National Institute of Health [NIH]) and EMBASE database (March 1962–March 2019) using keyword combinations of the medical subject headings (MeSH) of “cachexia,” “weight loss,” “anorexia,” “body composition,” “muscle wasting,” “energy balance,” “malnutrition,” “cancer,” and “neoplasm.” Relevant reference lists were also manually searched.

Definition of Cachexia
Cachexia is defined as a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle mass with or without loss of fat mass. Cachexia itself has been known for centuries. Cachexia was first described by Hippocrates as “the flesh is consumed and becomes water… the abdomen fills with water, the feet and legs swell, the shoulders, clavicles, chest, and thighs melt away… The illness is fatal.” The term cachexia is derived from the Greek words kakós, meaning “bad things,” and hexis, meaning “condition or appearance.”

A consensus meeting was recently held to define cachexia, finally reaching a clinical definition that can be applied in almost any clinical entity. It was eventually published in 2008. The definition that emerged is: “cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass.” The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, low food intake, and lack of response to anticancer therapy. Patients who have more than 5% loss in 12 months or less in the presence of underlying illness, plus three of the following:

- Decreased muscle strength (lowest percentile)
- Fatigue
- Anorexia
- Low fat-free mass index
- Abnormal biochemistry
  - Increased inflammatory markers CRP (>5.0 mg/L), IL-6 >4.0 pg/mL
  - Anemia (<12 g/dL)
  - Low serum albumin (<3.2 g/dL)

Abbreviation: CRP, C-reactive protein.

Stages of Cachexia in Cancer
Cancer cachexia is a continuum (with three stages of clinical relevance: pre-cachexia, cachexia, and refractory cachexia. Not all patients traverse the entire spectrum. In precachexia, early clinical and metabolic signs (e.g., anorexia and impaired glucose tolerance) can precede substantial involuntary weight loss (i.e., ≤5%). The risk of progression varies and depends on factors such as cancer type and stage, the presence of systemic inflammation, low food intake, and lack of response to anticancer therapy. Patients who have more than 5% loss of stable body weight over the past 6 months, or a BMI <20 kg/m² and ongoing weight loss of more than 2%, or sarcopenia and ongoing weight loss of more than 2%, but have not entered the refractory stage, are classified as having cachexia. In refractory cachexia, the cachexia can be clinically refractory as a result of very advanced cancer (preterminal) or the presence of rapidly progressive cancer unresponsive to anticancer therapy. This stage is associated with active catabolism, or the presence of factors that render active management of weight-loss no longer possible or appropriate. Refractory cachexia is characterized by a low performance status (World Health Organization [WHO] score 3 or 4) and a life expectancy of less than 3 months.
Mechanism of Cachexia in Cancer

Cachexia is characterized by a combination of events. There is a negative protein and energy balance driven by a combination of reduced food intake and abnormal metabolism. There are several proposed mechanism of cancer cachexia (Fig. 1).

Cytokines, Inflammation, and Hypermetabolic State

Increases in resting energy expenditure (REE; also called basal metabolic rate) may contribute to the energy deficits that lead to wasting. An increase in REE, as measured by indirect calorimetry, has been observed in patients with lung cancer and sarcomas, and it is thought to contribute to the weight loss observed in cancer cachexia.

Numerous cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, and interferon-gamma (IFN-γ) have been postulated to play a role in the etiology of cancer cachexia. Cytokines activate nuclear transcription factor κB (NF-κB) that results in decreased muscle protein synthesis. Cytokine activation is also responsible for the reduction of MyoD protein, a transcription factor that modulates signaling pathways involved in muscle development, resulting in muscle wasting.

Lipolysis and Lipid-Mobilizing Factor

Although wasting of lean body mass is a major aspect of cancer cachexia, loss of fat mass also occurs. A tumor-produced lipid-mobilizing factor (LMF) may contribute to wasting of fat tissue. It is postulated that LMF acts to sensitize adipose tissue to lipolytic stimuli by increasing cyclic adenosine monophosphate (AMP) production in adipocytes. This effect may be mediated through the β-adrenergic receptor, with increased receptor number or G-protein expression.

The ATP–Ubiquitin–Proteasome Pathway

Activation of the adenosine triphosphate (ATP)-ubiquitin-proteasome pathway may play an important role in cancer-associated tissue wasting as illustrated by two experimental study on animal found that free ubiquitin and ubiquitin conjugates were higher in gastrocnemius muscle of tumor-implanted rats than in muscles from control rats and that inhibition of the ubiquitin-proteasome pathway with the proteasome inhibitor MG132 can ameliorate cachexia in tumor-bearing mice. Thus, the ubiquitin-proteasome pathway may be the final common pathway mediating protein degradation in cachexia.

Reduced Dietary Intake or Absorption

Anorexia and poor oral intake contribute to the energy deficits observed in cancer cachexia. Hormones and mediators, like leptin and serotonin (5-HT), may play role in the development of cancer-induced anorexia. Leptin reduces appetite and increases energy expenditure via central nervous system. Thus, if a disease processes, such as cancer was to produce factors that induce or mimic the hypothalamic effect of excess negative feedback signaling from leptin, the expected outcome would be sustained anorexia (lack of appetite) and cachexia (muscle wasting and uncontrolled weight loss), without the usual compensatory response. Increased level of plasma and brain tryptophan, the precursor of 5-HT, and IL-1 may underlie the increased serotonergic activity seen in the cancer cachexia. The 5-HT activates various serotonin receptor subtypes in the gastrointestinal tract and ganglia, exerting a range of biological and physiological effects, such as nausea and vomiting, which can induces anorexia.
Chemotherapy-related alterations in taste and smell may also contribute to this loss of appetite.30

**Myostatin and Insulin-Like Growth Factor-1**

Myostatin is an extracellular cytokine that is mostly expressed in skeletal muscles and is known to play a crucial role in the negative regulation of muscle mass.31 Upon binding to the activating type-IIB receptor, myostatin can initiate several different signaling cascades, resulting in decreased muscle growth and differentiation.31 Transgenic mice with the myostatin gene develop a cachexia-like syndrome that manifests with severe wasting.32 On the other side, insulin-like growth factor-I (IGF-1) is highly sensitive to food intake. Under normal conditions, IGF-1 signaling seems to be dominant and blocks the myostatin pathway. However, an inhibition of IGF-1 can occur when myostatin is overexpressed.33 It was shown that in the absence of IGF-1, the level of apoptosis in C2C12 cells treated with myostatin increased,34 and the levels of IGF-1 is reduced in experimental models of cachexia.34

**Impact of Cachexia on Cancer**

Cachexia has marked effects on QOL, physical function, and mortality in cancer patients when compared with weight-stable patients. One reason for these effects may be related to the increased toxicity related to cancer-directed treatments with body composition changes.35 Drug doses are typically administered on the basis of body surface area, which does not account for muscle loss (i.e., sarcopenia, cachexia), fat gain, or water retention.36 Consequently, the volume of distribution of cancer treatments can be impacted not only from a change in lean body mass, but also from changes in fat mass and total body water. This change in volume of distribution may decrease the effectiveness and/or increase toxicities of cancer directed therapies. Body composition changes as a predictor of toxicity have been documented in breast, lung, esophageal, and colon cancers.37

Cachexia negatively impacts on surgical risk and response to chemotherapy and radiotherapy and ultimately results in decreased QOL.38 Cancer patients experiencing weight loss leading up to and during chemotherapy receive a lower initial dose and experience more frequent and severe dose-limiting toxicity when compared with weight-stable patients.35,37 Consequently receiving significantly less treatment. These patients also experienced decreased QOL, performance status and survival intervals and lowered response to treatment.

**Screening of Cancer Cachexia**

Cachexia screening is performed with the aim of increasing awareness and enabling early recognition and treatment. To detect cachexia at an early stage and to detect its acceleration, regular evaluation of weight change and BMI are needed, beginning at cancer diagnosis and repeated depending on the stability of the clinical situation. Mandatory screening for weight loss in patients with cancer has been established in some countries,38 with the intent of detecting in-hospital malnutrition.

Until now, there are no common assessment tools or validated measurements for screening of cachexia in cancer patients. Due to the lack of a specific cachexia assessment tool, malnutrition assessment tools are used in daily practice (Table 3).39 The most commonly used malnutrition assessment tools are patient-generated subjective global assessment (PG-SGA),40 mini–nutritional assessment (MNA),41 malnutrition-screening tool (MST),42 malnutrition universal screening tool (MUST),43 and nutritional risk screening-2002 (NRS-2002).44 The current malnutrition assessment tools are helpful to screen for malnutrition in health care and these tools are utilized to recommend nutritional support but they do not guide multimodal cachexia therapy. The malnutrition assessment tools only marginally assess the impact of cachexia, whether physical or psychosocial. Some of the instruments include performance status, others ask about depression, but functional impairment caused by cachexia and eating-related distress is not part of the established tools.39

**Diagnosis of Cachexia in Cancer Patient**

In the daily routine, very often the diagnosis of cachexia in cancer patients is made on the basis of a reduced food intake. Because of the complex condition of cancer patients, this could be misleading because the reduction of ingested

<table>
<thead>
<tr>
<th>Stores depletion</th>
<th>PG-SGA</th>
<th>MNA</th>
<th>MST</th>
<th>MUST</th>
<th>NRS 02</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle mass and strength</td>
<td>x̅</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Anorexia or reduced food intake</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Catabolic drivers</td>
<td>(x)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Functional and psychological effects</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

Abbreviations: MNA, mini–nutritional assessment; MST, malnutrition-screening tool; MUST, malnutrition universal screening tool; NRS, nutritional risk screening; PG-SGA, patient-generated subjective global assessment.

*Only physical examination.

*Only calf circumference.

*Only fever and corticosteroids.
calories might be the consequence of dysphagia or depression rather than a sign of cachexia. The diagnosis of CACS is complex and requires therefore a meticulous clinical examination of the patient (Table 4).45

Assessment of Weight Loss
The presence of weight loss is an important clinical sign that can even be the first detectable manifestation of the presence of cancer and can be easily obtained by patients and caregivers or measured by health care providers.46 After the possibility of intentional weight loss (for example, by dieting) has been excluded, alternative causes of weight loss of unknown origin are investigated. Weight loss is typically the first element of a cachexia diagnosis, so the presence of unintentional weight loss of more than 5% of premorbid weight in a 6 months period should be assessed.12,46 Weight loss varies in its severity: a 5% loss is considered the threshold of major risk of poor clinical outcome,47 with increasing risk as weight loss cumulatively reaches 10, 15, 20%, or higher.47

Assessment of Body Composition
One of the criteria for diagnosing cachexia according to International Consensus is appendicular muscle mass index

Table 4 Diagnosis of cancer cachexia45
<table>
<thead>
<tr>
<th>Test</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td>Unintentional weight loss (&gt;5% during preceding 6 months)</td>
</tr>
<tr>
<td>Skeletal muscle mass</td>
<td>Decreases biceps, quadriceps, muscle mass</td>
</tr>
<tr>
<td>Food intake recall or diary</td>
<td>Anorexia and/or decreased food intake</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Increased</td>
</tr>
<tr>
<td>Range of motion</td>
<td>Usually impaired</td>
</tr>
<tr>
<td>Karnofsky’s Performance Scale</td>
<td>Decreased scores</td>
</tr>
<tr>
<td>Serum</td>
<td></td>
</tr>
<tr>
<td>Serum C-reactive protein</td>
<td>Increased (acute-phase response)</td>
</tr>
<tr>
<td>Serum fibrinogen</td>
<td>Increased (acute-phase response)</td>
</tr>
<tr>
<td>Serum hematocrit</td>
<td>Decreased (anemia)</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>Decreased</td>
</tr>
</tbody>
</table>

Table 5 Measurement of cachexia parameters45-51
<table>
<thead>
<tr>
<th>Measurement</th>
<th>Tools</th>
<th>Cut-off value (kg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendicular skeletal muscle mass index</td>
<td>Bioimpedance analysis</td>
<td>Men 7</td>
</tr>
<tr>
<td></td>
<td>Dual energy X-ray absorptiometry</td>
<td>Women 5.7</td>
</tr>
<tr>
<td>Lumbar skeletal muscle mass index</td>
<td>Computed tomography scan on L3</td>
<td>Men 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women 5.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women 46.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women 34.18</td>
</tr>
</tbody>
</table>

that consistent with sarcopenia. Because of this, a physical examination has to be performed to evaluate skeletal muscle wasting and loss of body fat. The most important muscles for such an assessment are the gastrocnemius, vastus lateralis, rectus abdominus, and biceps because these type-II fast-twitch muscles are most commonly affected in cancer cachexia.45

Recently, bioelectrical impedance analysis (BIA),46 computed tomography (CT) imaging analysis,49 and dual-energy X-ray absorptiometry (DXA)46 has been introduced as tool to evaluate body composition (Table 5). Bioelectrical impedance analysis can also be used to measure body composition based on the electrical properties of tissues so it can estimate body fat percentage, fat mass, fat-free mass, and total body water with the help of predictive equations. BIA, unfortunately, has been reported not to be as reliable as DXA for assessing body composition in cancer patients51; however, BIA can be used to calculate the phase angle which has been reported to predict poor survival in cancer patients.52

Both DXA and CT imaging both have high precision and specificity for discriminating individual tissue components and are the gold standard for body composition evaluation. DXA uses alternating high-energy and low-energy X-rays to analyze the differences between bone and soft tissue attenuating at different X-ray levels.50 It measure predominantly appendicular muscle. DXA has some limitations including inability to differentiate subsets of adipose tissue into intramuscular, visceral, and subcutaneous and lean body mass into muscle, organ, and tumor, as well as overestimation of lean body mass in settings when changes of >5% hydration status of cancer patients.56

CT is often used over time to monitor cancer and can be taken advantage of to serve as an assessment tool for body composition. CT imaging can discriminate between adipose tissue, bone, organs, and muscle including degree of fatty infiltration by Hounsfield’s units based on tissue-specific attenuation values using software programs including SliceOmatic (Tomovision, Magog, Canada), FatSeg, OsiriX, and ImageJ.53 This method measures body composition through the measurement of muscle tissue located on the level of L3 since it strongly correlates with total body skeletal muscle area.54,55 Limitations of CT imaging include exposure to radiation which can be minimized if CT scans used for standard of care in cancer staging are utilized.

Assessment of Quality of Life and Anorexia
Assessing QOL is critical endpoint in cancer patients with cachexia. The functional assessment of anorexia-cachexia
therapy (FAACT) scale consists of the functional assessment of cancer therapy general (FACT-G) scale, and the anorexia–cachexia subscale (ACS) and is a QOL scale specific for cancer patients with cachexia.58 FAACT scale includes five subscales: (1) seven items for physical well-being, (2) six items for emotional well-being, (3) seven items for social well-being, (4) seven items for functional well-being, and (5) 12 items for ACS with each item rated as a five-level scoring system (0–4 points) with a higher sum of all 39-item score equating with a better QOL.56

Another questionnaire has been developed from The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) to measure QOL specifically in cancer patients with cachexia that is called EORTC QLQ-CAX24.57 It contains 24 items which consist of five multi-scale items (food aversion, eating and weight-loss worry, eating difficulties, loss of control, and physical decline) and four single items. This questionnaire can be used to achieve better measurement of QOL in cancer patients with cachexia.57

Biomarkers

When identifying and monitoring patients with cancer who have cachexia, it is important to acknowledge the potential role of biomarkers. One potential serum biomarker commonly used in clinical practice is C-reactive protein (CRP) which, when combined with additional factors of weight loss and nutritional intake, has identified patients at risk for cancer cachexia.58 Elevated CRP (>10 mg/L) has been linked with weight loss and has been confirmed in numerous studies.58,59 Low serum albumin (<35 g/L) has also been associated with weight loss.60

The modified Glasgow Prognostic Score, which is a combination of albumin and CRP, has been validated and reported to correlate with poor nutritional status and weight loss, decrease response to chemotherapy, and increased sensitivity to toxicities, and is a useful prognostic scoring tool.61 Ghrelin, obestatin, and leptin have also been studied as potential biomarkers for cachexia. Previous study has reported raised ghrelin serum levels in cancer patients with cachexia, whereas obestatin and leptin concentrations were found to be reduced.64

Pharmacologic Treatment

Corticosteroids

Corticosteroids are widely used as orexigenic agents,72 as they can exert a limited benefit in the management of cancer associated cachexia by improving appetite, caloric intake, pain control, inducing a sensation of wellbeing and reducing nausea. Prednisolone at a dose of 3 × 5 mg and dexamethasone 3 to 6 mg daily has been shown an appetite enhancement respect to placebo.73 Methylprednisolone given intravenously at a dose of 125 mg daily will ameliorate QOL. Nevertheless, these positive effects are of short duration and do not lead to an increase in body weight.75

Progestogens

Megestrol acetate (MA) and medroxyprogesterone acetate (MPA) are synthetic, orally active progestational agents. In several randomized controlled studies, these compounds have been found to improve appetite, caloric intake, and nutritional status in patients with nonhormone responsive tumors and cancer anorexia–cachexia syndrome.76–78 MA has demonstrated a dose-related beneficial effect, in a dose range from 160 to 1,600 mg/day on appetite, caloric intake, body weight gain (mainly fat), and sensation of wellbeing (with an optimal dosage of 800 mg daily).77,78 It is recommended that a patient is started on the lowest dosage (i.e., 160 mg/day) and that the dose is up-titrated according to clinical response.78,79 MPA has similarly been shown to increase appetite and food intake with a stabilization of body weight at a dose of 1,000 mg (i.e., 500 mg twice daily).78,79 Although the drug is safe at doses of 500 to 4,000 mg daily, side effects have been shown to increase above oral doses of 1,000 mg.76

Cannabinoids

Tetrahydrocannabinol (THC) and its derivatives are synthetic pharmaceuticals able to activate cannabinoid receptors and in particular, the CB1 receptors localized in the hypothalamus and the limbic system. Cannabinoids have been investigated...
in patients with cancer for antiemetic and appetite-stimulant activity. Dronabinol is the synthetic oral form of tetrahydrocannabinol (THC), which is the active agent in marijuana thought to be responsible for these effects. The mechanism of action of dronabinol is not completely understood, but its activity is likely mediated by cannabinoid receptor-related processes.

**Ghrelin**

Ghrelin is a 28-amino acid peptide hormone mostly produced in the stomach but also in other gastrointestinal tissues. It induces the release of growth hormone from the pituitary gland, stimulates food intake and also suppress the production of proinflammatory cytokines. In 2007, DeBoer et al observed a significant increase in food intake and weight gain after administration of human ghrelin or a synthetic ghrelin analogue BIM-28131 in a rat model of cancer-associated cachexia. At present, a phase-II randomized, placebo-controlled, double-blind study, using an oral ghrelin mimetic, demonstrated an improvement in lean body mass, total body mass, and hand-grip strength in cachectic cancer patients. Several clinical trials with ghrelin are currently on going.

**Thalidomide**

TNF-α, IL-6, and IFN-γ have all been implicated in the pathogenesis of cachexia. Thalidomide (α-N-phthalimido glutarimide) has complex immune-modulatory and anti-inflammatory properties. Thalidomide has been shown to counter TNFα and IL-6 production. One randomized placebo-controlled trial in patients with cancer cachexia showed that the drug was well-tolerated and effective at attenuating loss of weight and lean body mass in patients with advanced pancreatic cancer.

**Omega-3 Fatty Acids**

Eicosapentaenoic acid (EPA) is one of several omega-3 polyunsaturated fatty acids found abundantly in fish oil. Polyunsaturated fatty acids have been proposed to reduce cachexia-associated tissue wasting, as well as tumor growth. EPA downregulates the production of proinflammatory cytokines in both healthy individuals and patients with cancer. Furthermore, the effects of proteolysis inducing factor, a cachectic factor produced by cancer, are also inhibited by EPA.

**Conclusion**

Patients with cancer are the population at risk to develop cachexia before and after chemotherapy. The loss of weight that happens during chemotherapy will make a poor prognosis. Cachexia can worse chemotherapy toxicity. Cachexia diagnosis needs evaluation of body weight, food intake, and body composition. Dietary modification and physical exercise is the best strategy for cachexia in cancer patients. Some medications that alter appetite and inflammatory cytokines can be added to improve QOL.

**Conflict of Interest**

None declared.

**References**

17. Haslett PA, Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25(2(suppl 6)):53–57

Asian Journal of Oncology   Vol. 6   No. 3/2020
Cachexia in Cancer Patients

28 Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999;59(18):4493–4501
37 Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol 2011;22(1):11–48
58 Tan BH, Deans DA, Skipworth RJ, Ross JA, Fearon KC. Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer 2008;16(3):229–234
60 Krzyzek-Korpacka M, Matusiwicki M, Dlouhoszka D, et al. Acute-phase response proteins are related to cachexia and...


